ESM immune kinase inhibitor

ESM immune kinase inhibitor is a discovery-stage small molecule therapeutic being developed by Macrophage Pharma for the treatment of autoimmune disorders. The drug leverages the proprietary Engineered Small Molecule (ESM™) platform, which utilizes intracellular esterase enzymes to selectively trap and accumulate the active inhibitor within macrophages and other myeloid cells. This macrophage-targeting approach is intended to modulate immune signaling pathways driven by an unspecified immune kinase, potentially offering enhanced efficacy and a superior safety profile compared to systemic kinase inhibitors by concentrating the therapeutic effect at the site of inflammation.